IS4972A - Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm - Google Patents

Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm

Info

Publication number: IS4972A
Authority: IS; Iceland
Prior art keywords: pharmaceutical composition; alzheimer; disease; manufacture; treatment
Prior art date: 1996-08-13

Application number

IS4972A

Other languages

English (en)

Other versions

IS1907B (is

Inventor

Nikolas Gerolymatos Panayotis

Original Assignee

P.N. Gerolymatos S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-13

Filing date

1999-02-10

Publication date

1999-02-10

1999-02-10 Application filed by P.N. Gerolymatos S.A. filed Critical P.N. Gerolymatos S.A.

1999-02-10 Publication of IS4972A publication Critical patent/IS4972A/is

2003-12-16 Publication of IS1907B publication Critical patent/IS1907B/is

Links

QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 title abstract 3
229960005228 clioquinol Drugs 0.000 title abstract 3
239000008194 pharmaceutical composition Substances 0.000 title abstract 3
208000024827 Alzheimer disease Diseases 0.000 title 1
239000002738 chelating agent Substances 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
229930003779 Vitamin B12 Natural products 0.000 abstract 1
239000000969 carrier Substances 0.000 abstract 1
FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
239000011715 vitamin B12 Substances 0.000 abstract 1
235000019163 vitamin B12 Nutrition 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Neurology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Quinoline Compounds (AREA)

IS4972A 1996-08-13 1999-02-10 Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm IS1907B (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GR96100286		1996-08-13
PCT/IB1997/000983 WO1998006403A1 (en)	1996-08-13	1997-08-08	Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease

Publications (2)

Publication Number	Publication Date
IS4972A true IS4972A (is)	1999-02-10
IS1907B IS1907B (is)	2003-12-16

Family

ID=10942479

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS4972A IS1907B (is)	1996-08-13	1999-02-10	Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm

Country Status (25)

Country	Link
US (1)	US6001852A (is)
EP (1)	EP0959888B1 (is)
JP (1)	JP2000516606A (is)
KR (1)	KR100489969B1 (is)
CN (1)	CN1114407C (is)
AT (1)	ATE205086T1 (is)
AU (1)	AU720643B2 (is)
BR (1)	BR9711194A (is)
CA (1)	CA2264097C (is)
CZ (2)	CZ292411B6 (is)
DE (1)	DE69706566T2 (is)
DK (1)	DK0959888T3 (is)
ES (1)	ES2162319T3 (is)
HU (1)	HUP9903906A3 (is)
IL (1)	IL128416A (is)
IS (1)	IS1907B (is)
NO (1)	NO990595L (is)
NZ (1)	NZ334124A (is)
PL (1)	PL188838B1 (is)
PT (1)	PT959888E (is)
RU (1)	RU2193406C2 (is)
SI (1)	SI0959888T1 (is)
SK (1)	SK283117B6 (is)
TR (1)	TR199900293T2 (is)
WO (1)	WO1998006403A1 (is)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7045531B1 (en)	1997-03-11	2006-05-16	The General Hospital Corporation	Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
EP1007040B1 (en) *	1997-08-21	2002-05-08	P.N. Gerolymatos S.A.	Use of phanquinone for the treatment of alzheimer's disease
US6537969B1 (en) *	1997-10-24	2003-03-25	John P. Blass	Nutritional supplement for cerebral metabolic insufficiencies
US5994323A (en) *	1997-12-31	1999-11-30	P.N. Gerolymatos S.A.	Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
US20020025944A1 (en) *	2000-04-28	2002-02-28	Bush Ashley I.	Use of clioquinol for the therapy of Alzheimer's disease
US6638711B1 (en)	1999-04-29	2003-10-28	The General Hospital Corporation	Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
US20050112543A1 (en) *	1998-03-11	2005-05-26	The General Hospital Corporation	Method of screening for drugs useful in treating Alzheimer's disease
US6323218B1 (en)	1998-03-11	2001-11-27	The General Hospital Corporation	Agents for use in the treatment of Alzheimer's disease
DE60016892T2 (de) *	1999-01-07	2005-12-15	P.N. Gerolymatos S.A., Kryoneri	Verwendung von phanquinon zur behandlung und vorbeugung von gedächtnisschwund
US6692234B2 (en)	1999-03-22	2004-02-17	Water Management Systems	Pump system with vacuum source
BR0108303A (pt) *	2000-02-09	2003-03-05	Hokuriku Pharmaceutical	Derivados do 1h-imidazopiridina
FR2818551B1 (fr) *	2000-12-22	2007-06-01	Claude Marc Pierre Hannoun	Utilisation de chelateurs pour le traitement des maladies a prions
US6803379B2 (en) *	2002-06-04	2004-10-12	Jose A. Fernandez-Pol	Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets
AU2002950217A0 (en)	2002-07-16	2002-09-12	Prana Biotechnology Limited	8- Hydroxy Quinoline Derivatives
CA2500952C (en)	2002-10-04	2011-04-26	Prana Biotechnology Limited	Neurologically-active compounds
US20080063599A1 (en) *	2002-11-18	2008-03-13	Jorge Setoain Quinquer	Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
CN1791408A (zh) *	2003-04-03	2006-06-21	普拉纳生物技术有限公司	神经系统疾病的治疗
CA2546404A1 (en) *	2003-11-19	2005-06-02	Acrux Dds Pty Ltd.	Method and composition for treatment or prophylaxis of amyloidosis disorders
US20060194723A1 (en) *	2005-02-28	2006-08-31	Rabinoff Michael D	Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
CN102764279B (zh) *	2005-10-14	2015-04-01	全面技术公司	改变细胞功能的方法和组合物
US8871715B2 (en)	2005-10-14	2014-10-28	Alltech, Inc.	Use of selenium compounds, especially selenium yeasts for altering cognitive function
US8865763B2 (en)	2005-10-14	2014-10-21	Alltech, Inc.	Methods and compositions for altering cell function
PT1954718E (pt) *	2005-11-30	2014-12-16	Abbvie Inc	Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
KR20180058863A (ko) *	2005-11-30	2018-06-01	애브비 인코포레이티드	아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
US20100144693A1 (en)	2006-04-14	2010-06-10	Prana Biotechnology Limited	Method of treatment of age-related macular degeneration (amd)
SI2468770T1 (en) *	2006-07-14	2018-05-31	Ac Immune S.A.	A humanized antibody against amyloid beta.
PL2468770T3 (pl) *	2006-07-14	2018-07-31	Ac Immune S.A.	Humanizowane przeciwciało przeciw amyloidowi beta
RU2338542C1 (ru) *	2007-03-20	2008-11-20	Игорь Анатольевич Помыткин	Применение воды с пониженным содержанием дейтерия для приготовления средств лечения нейродегенеративных заболеваний и улучшения когнитивной функции
US8048420B2 (en)	2007-06-12	2011-11-01	Ac Immune S.A.	Monoclonal antibody
US8613923B2 (en)	2007-06-12	2013-12-24	Ac Immune S.A.	Monoclonal antibody
EP2586795B1 (en)	2007-10-05	2018-05-16	Genentech, Inc.	Use of anti-amyloid beta antibody in ocular diseases
ES2332687B1 (es) *	2008-03-13	2011-01-10	Proyecto De Biomedicina Cima, S.L.	Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
MY164579A (en)	2010-07-30	2018-01-15	Ac Immune Sa	Safe and functional humanized antibodies
FR2966827B1 (fr)	2010-10-27	2014-08-22	Kimonella Ventures Ltd	Compose peptidique utile pour l'inhibition de la formation de plaques amyloides
KR101802048B1 (ko) *	2013-04-02	2017-12-28	안지 파마슈티컬 코퍼레이션 리미티드	항신경퇴행성제로서의 다작용성 퀴놀린 유도체
JP6461922B2 (ja)	2014-04-24	2019-01-30	想い出創造株式会社	アミロイド線維形成の抑制又は阻害剤
KR20160057500A (ko) *	2014-11-05	2016-05-24	아카데미아 시니카	클리오퀴놀을 포함하는 자폐증 스펙트럼 장애의 치료용 약학적 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE393238C (de) *	1923-05-12	1924-03-31	Maschb Akt Ges H Flottmann & C	Bohrhammer
US3174899A (en) *	1960-12-30	1965-03-23	Ciba Geigy Corp	Composition for the management of post antibiotic enteritis
US3178343A (en) *	1962-11-27	1965-04-13	Ciba Geigy Corp	Pharmaceutical compositions and method of using same
DE1617417A1 (de) *	1966-12-08	1971-03-25	Ciba Geigy	Pharmazeutisches Praeparat
RU2057531C1 (ru) *	1986-07-01	1996-04-10	Всероссийский научный центр по безопасности биологически активных веществ	Средство для стимуляции обучения и памяти
DE3932338A1 (de) *	1989-09-28	1991-04-11	Nmi Naturwissenschaftl U Mediz	Verfahren zur praeventiven therapie von morbus alzheimer
GB9010039D0 (en) *	1990-05-03	1990-06-27	Reckitt & Colmann Prod Ltd	Medicament preparation
GB9108080D0 (en) *	1991-04-15	1991-06-05	Smithkline Beecham Plc	Pharmaceutical composition
US5206264A (en) *	1991-11-04	1993-04-27	Cypros Pharmaceutical Corporation	Use of disulfiram to prevent cardiovascular damage
AU669493B2 (en) *	1991-11-12	1996-06-13	University Of Melbourne, The	A method for assaying and treating Alzheimer's disease
US5607691A (en) *	1992-06-12	1997-03-04	Affymax Technologies N.V.	Compositions and methods for enhanced drug delivery
WO1995019178A1 (en) *	1994-01-13	1995-07-20	Research Foundation For Mental Hygiene, Inc.	Methods and compositions for treatment and diagnosis of alzheimer disease and other disorders
AU6580494A (en) *	1994-05-11	1995-12-05	P.N. Gerolymatos S.A.	Use of clioquinol for treating helicobacter, including (h. pylori), infections and related diseases
US5505958A (en) *	1994-10-31	1996-04-09	Algos Pharmaceutical Corporation	Transdermal drug delivery device and method for its manufacture

1997
- 1997-08-08 NZ NZ334124A patent/NZ334124A/xx unknown
- 1997-08-08 JP JP10509541A patent/JP2000516606A/ja active Pending
- 1997-08-08 PL PL97331822A patent/PL188838B1/pl not_active IP Right Cessation
- 1997-08-08 CZ CZ1999484A patent/CZ292411B6/cs not_active IP Right Cessation
- 1997-08-08 EP EP97932969A patent/EP0959888B1/en not_active Expired - Lifetime
- 1997-08-08 CZ CZ2003491A patent/CZ295118B6/cs not_active IP Right Cessation
- 1997-08-08 CN CN97197919A patent/CN1114407C/zh not_active Expired - Fee Related
- 1997-08-08 CA CA002264097A patent/CA2264097C/en not_active Expired - Fee Related
- 1997-08-08 BR BR9711194-5A patent/BR9711194A/pt not_active Application Discontinuation
- 1997-08-08 AU AU36324/97A patent/AU720643B2/en not_active Ceased
- 1997-08-08 DE DE69706566T patent/DE69706566T2/de not_active Expired - Lifetime
- 1997-08-08 PT PT97932969T patent/PT959888E/pt unknown
- 1997-08-08 KR KR10-1999-7001196A patent/KR100489969B1/ko not_active Expired - Fee Related
- 1997-08-08 HU HU9903906A patent/HUP9903906A3/hu unknown
- 1997-08-08 SI SI9730230T patent/SI0959888T1/xx unknown
- 1997-08-08 AT AT97932969T patent/ATE205086T1/de not_active IP Right Cessation
- 1997-08-08 IL IL12841697A patent/IL128416A/en not_active IP Right Cessation
- 1997-08-08 TR TR1999/00293T patent/TR199900293T2/xx unknown
- 1997-08-08 DK DK97932969T patent/DK0959888T3/da active
- 1997-08-08 SK SK179-99A patent/SK283117B6/sk not_active IP Right Cessation
- 1997-08-08 RU RU99105213/14A patent/RU2193406C2/ru not_active IP Right Cessation
- 1997-08-08 ES ES97932969T patent/ES2162319T3/es not_active Expired - Lifetime
- 1997-08-08 WO PCT/IB1997/000983 patent/WO1998006403A1/en not_active Ceased
1998
- 1998-02-13 US US09/023,544 patent/US6001852A/en not_active Expired - Lifetime
1999
- 1999-02-09 NO NO990595A patent/NO990595L/no not_active Application Discontinuation
- 1999-02-10 IS IS4972A patent/IS1907B/is unknown

Also Published As

Publication number	Publication date
CA2264097A1 (en)	1998-02-19
AU3632497A (en)	1998-03-06
SI0959888T1 (en)	2002-10-31
HUP9903906A3 (en)	2001-01-29
KR20000029958A (ko)	2000-05-25
CN1114407C (zh)	2003-07-16
NO990595D0 (no)	1999-02-09
EP0959888A1 (en)	1999-12-01
CZ292411B6 (cs)	2003-09-17
TR199900293T2 (xx)	1999-06-21
SK17999A3 (en)	1999-09-10
NO316768B1 (no)	1999-04-12
EP0959888B1 (en)	2001-09-05
ES2162319T3 (es)	2001-12-16
IL128416A0 (en)	2000-01-31
DE69706566D1 (de)	2001-10-11
KR100489969B1 (ko)	2005-05-17
PT959888E (pt)	2002-02-28
PL188838B1 (pl)	2005-04-29
WO1998006403A1 (en)	1998-02-19
CA2264097C (en)	2007-11-27
HUP9903906A2 (hu)	2000-04-28
CN1230115A (zh)	1999-09-29
IL128416A (en)	2004-06-01
NZ334124A (en)	2000-10-27
RU2193406C2 (ru)	2002-11-27
CZ295118B6 (cs)	2005-05-18
DK0959888T3 (da)	2001-11-05
BR9711194A (pt)	2000-01-11
DE69706566T2 (de)	2002-07-11
JP2000516606A (ja)	2000-12-12
HK1022437A1 (en)	2000-08-11
SK283117B6 (sk)	2003-02-04
IS1907B (is)	2003-12-16
AU720643B2 (en)	2000-06-08
PL331822A1 (en)	1999-08-02
ATE205086T1 (de)	2001-09-15
NO990595L (no)	1999-04-12
US6001852A (en)	1999-12-14
CZ48499A3 (cs)	1999-07-14

Publication	Publication Date	Title
IS4972A (is)	1999-02-10	Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm
MY127980A (en)	2007-01-31	A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
AU2002225772A1 (en)	2002-06-03	Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
MY111260A (en)	1999-10-30	Pharmaceutical composition for the treatment of nicotine dependence
MY118526A (en)	2004-11-30	Method for improving the pharmacokinetics of tipranavir
NO972391D0 (no)	1997-05-26	2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
GB9103764D0 (en)	1991-04-10	Compositions
PT1007040E (pt)	2002-10-31	Utilizacao de fanquinona no tratamento da doenca de alzheimer
NO943288L (no)	1995-03-22	Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
MX9707642A (es)	1997-12-31	Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
ES2093357T3 (es)	1996-12-16	Metodo de tratamiento de la alopecia.
AU1656997A (en)	1997-10-02	Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
MXPA02011533A (es)	2003-04-25	Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
NO990450L (no)	1999-01-29	Behandling av sinnslidelser
BG106151A (en)	2002-05-31	Pharmaceutical complex
SE9500897D0 (sv)	1995-03-14	The pharmacological use of certain cystine derivatives
FR2818147B1 (fr)	2005-06-10	Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine
FI972637A0 (fi)	1997-06-19	K-ryhmän vitamiinin käyttö lisäkilpirauhasen liikatoiminnan hoitoon